UK-based company Ubiquigent has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. UbiSite will form a new component in Ubiquigent’s deubiquitylase (DUB) and ubiquitin-proteasome system (UPS) focused drug discovery platform. UbiSite technology uses an antibody specific to the C-terminal of ubiquitin for the capture and further identification of protein […]
